7QS Stock Overview
Operates as a clinical-stage natural psychedelic drug development company in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Filament Health Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.01 |
| 52 Week High | US$0.04 |
| 52 Week Low | US$0.0005 |
| Beta | 1.02 |
| 1 Month Change | 0% |
| 3 Month Change | 185.71% |
| 1 Year Change | -53.49% |
| 3 Year Change | -90.57% |
| 5 Year Change | n/a |
| Change since IPO | -94.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7QS | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | 2.5% |
| 1Y | -53.5% | -17.6% | 13.4% |
Return vs Industry: 7QS underperformed the German Pharmaceuticals industry which returned -15.5% over the past year.
Return vs Market: 7QS underperformed the German Market which returned 15% over the past year.
Price Volatility
| 7QS volatility | |
|---|---|
| 7QS Average Weekly Movement | 562.6% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 7QS's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7QS's weekly volatility has increased from 283% to 563% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 13 | Ben Lightburn | filament.health |
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company’s leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage.
Filament Health Corp. Fundamentals Summary
| 7QS fundamental statistics | |
|---|---|
| Market cap | €2.99m |
| Earnings (TTM) | -€3.17m |
| Revenue (TTM) | €393.68k |
9.3x
P/S Ratio-1.2x
P/E RatioIs 7QS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7QS income statement (TTM) | |
|---|---|
| Revenue | CA$616.68k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$616.68k |
| Other Expenses | CA$5.59m |
| Earnings | -CA$4.97m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 100.00% |
| Net Profit Margin | -805.98% |
| Debt/Equity Ratio | 0% |
How did 7QS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 19:44 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Filament Health Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | NOBLE Capital Markets, Inc. |
| Robert Sassoon | Water Tower Research LLC |